July 13, 2026 02:07 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Highway blocked, stones pelted, cops injured': BJP faces open revolt in Madhya Pradesh over Narottam Mishra ticket snub | Two Kolkata Police DCPs suspended over alleged remarks against Bengal CM Suvendu Adhikari | Bail to Bloodbath: Telangana man allegedly kills wife, kids and teen who accused him of sexual harassment | Prakash Raj gets bail in multiple voter registration case linked to 2019 polls | ED raids Shekhar Suman associate's premises in FEMA case; phone allegedly thrown from 13th floor | 'Candidate fled': Prashant Kishor jibes BJP over Bankipur nominee change | BJP replaces candidate days before high-stakes Bankipur bypoll | Foreign franchise league enters India! BBL opener to be played in Chennai, announce Modi-Albanese | 'They could have stopped me': Vijay blames police, former DMK government over Karur stampede | 'People will correct their 2025 mistake': Electoral debutant Prashant Kishor predicts BJP defeat in Bankipur

Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

| | Jun 23, 2015, at 10:54 pm
New Delhi, June 23 (IBNS) Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Levofloxacin Tablets, 250mg and 500mg, the generic version of Levaquin Tablets (of Ortho-McNeil), which is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.

The total market size for Levofloxacin Tablets as per IMS is $28 Million per annum.

As on Mar 31, Jubilant Life Sciences had a total of 806 filings for formulations of which 368 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm